Search results for "Renal Cell"

showing 10 items of 231 documents

Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma

2022

Background: Statins are widely used in an ageing population, including subjects with solid malignancies. However, no conclusive evidence is currently available on their potential influence on patients' outcome. We aimed to assess whether statin exposure affects the survival of patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.Patients and methods: Medical records of patients with documented mRCC treated with second- or third-line nivolumab were reviewed at ten institutions from Italy, Spain and the USA. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit. Univariate and multivariate analyses were used to e…

Cancer ResearchSurvivalTumour responseStatinRenal cell carcinomaProgression-Free SurvivalKidney NeoplasmsNivolumabTreatment OutcomeOncologyChild PreschoolHumansImmunotherapyHydroxymethylglutaryl-CoA Reductase InhibitorsConcomitant medicationsCarcinoma Renal CellRetrospective Studies
researchProduct

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responsesin vitro

2006

Human tumors frequently escape immune destruction, despite the presence of cytotoxic T cells (CTL) recognizing tumor-associated antigens (TAA). We have previously shown that programmed death ligand-1 (PD-L1), a recently identified ligand of the B7 superfamily, is expressed on murine tumors and can inhibit antitumor immune responses. To evaluate the clinical relevance of our animal model findings, we examined human tumors and tumor-specific T cells. We found PD-L1 to be constitutively expressed on human renal cell carcinoma (RCC) cell lines and upregulated on human melanoma cell lines upon exposure to interferon-gamma. Similarly, we found binding of anti-PD-L1 monoclonal antibody (mAb) on fr…

Cancer ResearchT cellAntineoplastic AgentsB7-H1 AntigenInterleukin 21Immune systemAntigenAntigens CDTumor Cells CulturedmedicineHumansCytotoxic T cellCTLA-4 AntigenIL-2 receptorAntigen-presenting cellCarcinoma Renal CellMelanomabusiness.industryAntibodies MonoclonalFlow CytometryAntigens DifferentiationImmunohistochemistryKidney NeoplasmsUp-RegulationGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyImmunologyB7-1 AntigenCancer researchbusinessB7-H1 AntigenT-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors

2002

The Tap1 and Tap2 genes encoding for a heterodimeric peptide transporter play a key role in antigen processing and presentation. The TAP complex mediates the transport of peptides generated by the IFN-gamma-inducible proteasome subunits LMP2, 7 and 10 from the cytosol into the endoplasmic reticulum (ER), where they bind to MHC class I molecules. In contrast to the frequent polymorphisms within the rat Tap genes which exert functional differences, polymorphic regions within the human Tap genes have been demonstrated, but not systematically analyzed in terms of their functional significance. Both the Tap1 and Lmp2 genes are transcribed from a bidirectional intergenic promoter which is regulat…

Cancer ResearchTransfectionViral Matrix ProteinsIntergenic regionGene FrequencyGenotypeMHC class ITumor Cells CulturedAnimalsHumansRNA MessengerATP Binding Cassette Transporter Subfamily B Member 2Promoter Regions GeneticCarcinoma Renal CellMelanomaGeneGeneticsPolymorphism GeneticbiologyReverse Transcriptase Polymerase Chain ReactionAntigen processingEndoplasmic reticulumMolecular biologyGene Expression Regulation NeoplasticOncologyCOS Cellsbiology.proteinTAP2ATP-Binding Cassette TransportersTAP1International Journal of Oncology
researchProduct

The FHIT gene is alternatively spliced in normal kidney and renal cell carcinoma.

1997

FHIT (Fragile Histidine Triad), a putative tumor suppressor gene, was cloned from fetal brain and colon cDNA libraries. Portions of this gene are deleted in esophageal, colon, lung and breast tumors, but this gene has not been found altered in sporadic renal cell carcinomas. We report here an alternatively spliced form of this gene cloned from a kidney cDNA library. This cDNA is 1189 bp in length, and contains an additional 94 bp exon, designated exon 2a (E2a). This novel sequence is located between exon 2 and exon 3 of the FHIT gene's untranslated region and exon 2a is present in all normal kidney tissues and cell lines. Analyses performed on sporadic renal cell carcinoma (RCC) tissues and…

Cancer ResearchTumor suppressor geneMolecular Sequence DataBiologymedicine.disease_causeKidneyPolymerase Chain ReactionExonFHITComplementary DNAGene expressionGeneticsmedicineHumansGenes Tumor SuppressorAmino Acid SequenceCloning MolecularneoplasmsMolecular BiologyCarcinoma Renal CellBase SequencecDNA libraryAlternative splicingProteinsBlotting NorthernKidney NeoplasmsAcid Anhydride HydrolasesNeoplasm ProteinsAlternative SplicingCancer researchCarcinogenesisOncogene
researchProduct

A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile.

2019

e16109 Background: Predicting which patient with metastatic renal cell carcinoma (mRCC) will benefit from immune checkpoints inhibitors (ICPIs) still remain an issue. Biological factors particular to certain individuals have a clear effect on variation in response. Emerging evidence suggests that small non-coding RNA, such as microRNAs (miRNAs), are critical modulators of numerous cellular processes, including immune surveillance. The main aim of this study was to analyze the lymphocyte miRNA expression profile in mRCC patients and dynamic changes after the treatment with ICPI, in order to investigate the molecular mechanisms and signaling pathways involved in ICPI response and their poten…

Cancer Researchbusiness.industryLymphocytemedicine.medical_treatmentMicroRNA Expression ProfileImmunotherapymedicine.diseasemedicine.anatomical_structureImmune systemOncologyRenal cell carcinomamedicineCancer researchbusinessPredictive biomarkerJournal of Clinical Oncology
researchProduct

In the literature: August 2020.

2020

Immune checkpoint inhibitors (ICI) have become a key component of therapy for several solid tumours. In patients diagnosed with advanced clear cell renal cell carcinoma (ccRCC), immunotherapy has always been considered as a treatment option, and anti-PD-1-based therapies are approved in both the frontline and refractory settings. Response to PD-1 blockade has been associated with numerous tumour-intrinsic and microenvironment features. Genetic characterisation of ccRCC has significantly contributed to the knowledge of tumour biology and the mechanisms of disease progression, but the interplay of genomic alterations with patterns of immune infiltration in response to PD-1 blockade remains un…

Cancer Researchbusiness.industrymedicine.medical_treatmentImmunotherapyNewsmedicine.diseasePBRM1Blockadenot applicableTranscriptomeClinical trialClear cell renal cell carcinomaImmune systemOncologymedicineCancer research1506businessCD8ESMO open
researchProduct

Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas

1994

The gp80 glycoprotein complex (clusterin, apolipoprotein J, TRPM-2) is a widely expressed protein that has been attributed functions in tissue remodelling, immune defense and transport of lipids and biologically active peptides. The expression of the protein appears to be elevated in several neurodegenerative, apoptotic and malignant processes. We show here that in patients with renal clear cell carcinoma gp80 mRNA is 3-fold overexpressed in tissue of the tumors compared with adjacent non-tumor tissue.

Cancer Researchmedicine.medical_specialtyBiologyKidneyTRPMGlycoprotein complexInternal medicinemedicineHumansRNA MessengerRNA NeoplasmCarcinoma Renal CellGlycoproteinsKidneyMessenger RNAClusterinGeneral MedicineBlotting NorthernKidney NeoplasmsNeoplasm ProteinsClusterinEndocrinologymedicine.anatomical_structureOncologyApoptosisClear cell carcinomaCancer researchbiology.proteinClear cellMolecular ChaperonesJournal of Cancer Research and Clinical Oncology
researchProduct

Differential inhibition of renal cancer cell invasion mediated by fibronectin, collagen IV and laminin.

2000

Invasion of tumor cells into the extracellular matrix is an essential step in the formation of metastases in renal cancer. Cell adhesion molecules such as beta(1)-integrins, which bind to the RGD sequence (arginine-glycine-asparagine) and CD44 are involved in this process. We examined the invasion of a renal carcinoma cell line (CCF-RC1) into the extracellular matrix compounds fibronectin, collagen IV and laminin and the effect of TGFbeta and IFNgamma on this process. The inhibitory effect of an antibody against the beta(1)-subunit of integrins (CD29), as well as a pentapeptide including the RGD sequence, was also evaluated. A micro-chemotaxis chamber, including a polycarbonate membrane wit…

Cancer Researchmedicine.medical_specialtyIntegrinExtracellular matrixInterferon-gammaLamininCell MovementTransforming Growth Factor betaInternal medicinemedicineTumor Cells CulturedHumansNeoplasm InvasivenessCarcinoma Renal CellbiologyDose-Response Relationship DrugCell adhesion moleculeChemotaxisIntegrin beta1CD44Cell migrationCD29Kidney NeoplasmsCell biologyExtracellular MatrixFibronectinsFibronectinEndocrinologyHyaluronan ReceptorsOncologybiology.proteinCollagenLamininOligopeptidesCancer letters
researchProduct

Malignant fibrous histiocytoma of the renal capsule

1981

We report about an extremely rare case of malignant fibrous histiocytoma (MFH) of the renal capsule. The tumor is composed of fibroblast-like cells arranged in a storiform pattern and histiocyte-like cells with multinucleated giant cells, both showing no iron reaction. Characteristic of the histiocytic quality of the tumor are numerous PAS-positive intracytoplasmic droplets which can be identified as erythrophagosomes only under the electron microscope. Emphasis is put on the preoperative differential diagnosis of the tumor from renal cell carcinoma as well as on its histogenesis and prognosis.

Cancer Researchmedicine.medical_specialtyPathologyHistogenesislaw.inventionDiagnosis DifferentialRenal capsulelawRenal cell carcinomaInternal medicinemedicineHumansHistiocyteAgedHematologyHistiocytoma Benign Fibrousbusiness.industryGeneral Medicinemedicine.diseaseKidney Neoplasmsmedicine.anatomical_structureOncologyGiant cellFemaleDifferential diagnosisElectron microscopebusinessJournal of Cancer Research and Clinical Oncology
researchProduct

A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.

2014

e15588 Background: The stratification of poor risk mRCC patients in the era of targeted therapy represents an unmet medical need. We analyzed, individually, each prognostic factor included in modif...

Cancer Researchmedicine.medical_specialtyPrognostic factorPoor riskbusiness.industrymedicine.medical_treatmenturologic and male genital diseasesmedicine.diseasePrognostic stratificationStratification (mathematics)Targeted therapyOncologyRenal cell carcinomaMedicinebusinessIntensive care medicine
researchProduct